St. Jude Clinical Trials
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.